Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | FLT1 | P17948 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | BLM | P54132 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | TOP1 | P11387 | 3/20 | 0.56 |
| ▸ | TOP2A | P11388 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 3/20 | 0.55 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14399402 | 0.82 | ALDH1A1 (0.80) | ALDH1A1SMN1; SMN2FGFR1KDM4EFLT1 | |
| SCHEMBL18833326 | 0.81 | FGFR1 (0.62) | ALDH1A1SMN1; SMN2FGFR1KDM4EFLT1 | |
| SCHEMBL14656343 | 0.81 | ALDH1A1 (0.80) | ALDH1A1SMN1; SMN2FGFR1KDM4EFLT1 | |
| SCHEMBL14090247 | 0.80 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2FGFR1KDM4EFLT1 | |
| SCHEMBL8769012 | 0.79 | ALDH1A1 (0.72) | ALDH1A1SMN1; SMN2FGFR1KDM4EFLT1 | |
| SCHEMBL12834057 | 0.79 | FGFR1 (0.71) | ALDH1A1SMN1; SMN2FGFR1KDM4EFLT1 | |
| SCHEMBL12833916 | 0.78 | FGFR1 (0.67) | ALDH1A1SMN1; SMN2FGFR1KDM4EFLT1 | |
| SCHEMBL18155063 | 0.77 | MET (0.54) | ALDH1A1SMN1; SMN2FGFR1KDM4EFLT1 | |
| SCHEMBL30580360 | 0.77 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2FGFR1KDM4EFLT1 | |
| SCHEMBL26252722 | 0.77 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2FGFR1KDM4EFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | ALDH1A1 2293/4885SMN1; SMN2 3752/4885FGFR1 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.